Avestar Capital’s Cardiff Oncology CRDF Stock Holding History

Avestar Capital’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$177K	Hold	136,145	–	–	0.01%	523
2026 Q1	$221K	Hold	136,145	–	–	0.01%	472
2025 Q4	$383K	Sell	136,145 -4,324	-3%	-$10K	0.02%	382
2025 Q3	$289K	Hold	140,469	–	–	0.02%	417
2025 Q2	$442K	Hold	140,469	–	–	0.03%	333
2025 Q1	$441K	Hold	140,469	–	–	0.04%	306
2024 Q4	$610K	Hold	140,469	–	–	0.05%	250
2024 Q3	$375K	Hold	140,469	–	–	0.04%	299
2024 Q2	$312K	Buy	+140,469	New	+$529K	0.03%	331

Other funds holding CRDF

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Avestar Capital's CRDF Position: Q2 2026 in Review

Avestar Capital held its Cardiff Oncology (CRDF) position steady in Q2 2026 at 136,145 shares worth $177K. The position accounts for 0.01% of the portfolio, ranked #523.

Avestar Capital first reported a position in CRDF in Q2 2024 and has held it in 9 quarters since. The position peaked at $610K in Q4 2024. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

Avestar Capital held 136,145 shares of Cardiff Oncology worth $177K as of Q2 2026.
Avestar Capital left its Cardiff Oncology share count unchanged in Q2 2026.
Cardiff Oncology made up 0.01% of Avestar Capital's portfolio in Q2 2026, its #523 holding.
Avestar Capital first reported a position in Cardiff Oncology in Q2 2024 and has held it in 9 quarters since.
Avestar Capital's Cardiff Oncology position peaked at $610K in Q4 2024.
105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on Avestar Capital's 13F filing for Q2 2026, filed 29 Jul 2026.